Targets › PLG
9 programs from 9 companies in 62 trials: 22 Phase 4, 21 Phase 3, 16 Phase 2, 3 Phase 1; Other, Cardiovascular, Gastroenterology; next expected readout Dec 2026.
[Plasmin]: Protease which primary function is to degrade fibrin, the main component of blood clots. Also cleaves other components of blood clots like thrombospondin-1/THBS1 and von Willebrand factor (VWF). (UniProt, P00747)
Open in Phaseline: the race on PLG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Health Network, Toronto | Topical Tranexamic Acid Antifibrinolytic agent that inhibits plasminogen activation and fibrinolysis | PLG | Phase 4 | Distal Radius Fractures | Dec 2026 |
| The First Affiliated Hospital with Nanjing Medical University | Recombinant staphylokinase (r-SAK) Serine protease fibrinolytic enzyme that directly activates plasminogen to plasmin | PLG | Phase 4 | ST Elevation Myocardial Infarction | Dec 2026 |
| Massachusetts General Hospital | Topical Tranexamic acid Plasminogen inhibitor | PLG | Phase 4 | Drain Output After Breast Reduction Surgery | Mar 2027 |
| Youssef Yammine | Tranexamic acid Plasminogen inhibitor | PLG | Phase 3 | Hemorrhage Lung | Mar 2028 |
| Supergene | Non-immunogenic recombinant staphylokinase (Fortelyzin®) Staphylokinase, a plasminogen activator | PLG, PLMN | Phase 3 | Acute Limb Ischemia; Pulmonary Embolism; Ischemic Stroke, Acute | Jun 2028 |
| New York Medical College | Defibrotide Adenosine A2 receptor agonist; Plasminogen activator; Adenosine A1 receptor agonist | ADORA2B, ADORA2A, PLG, ADORA1, F2 | Phase 2 | Sickle Cell Disease; Sinusoidal Obstruction Syndrome | Dec 2026 |
| Jiangsu Jingze Biopharmaceutical | Recombinant Human Truncated Plasmin Injection (JZB32) Serine protease (truncated plasmin) that cleaves fibrin and other extracellular matrix pro | PLG | Phase 2 | Vitreomacular Traction (VMT) | Dec 2027 |
| Children's National Research Institute | Aminocaproic Acid Plasminogen inhibitor; Tissue-type plasminogen activator inhibitor | PLG, PLAT | Phase 2 | Craniosynostosis | Jan 2028 |
| Ascension Health | Tranexamic acid Plasminogen inhibitor | PLG | Phase 2 | Postoperative Blood Loss; Knee Osteoarthritis; Hemorrhage; Melasma … | – |
Postpartum Hemorrhage (3) Trauma Coagulopathy (2) Post Burn Facial Hyperpigmentation (2) ST Elevation Myocardial Infarction (1) Sickle Cell Disease (1) Sinusoidal Obstruction Syndrome (1) Distal Radius Fractures (1) Postoperative Blood Loss (1) Knee Osteoarthritis (1) Hemorrhage (1) Melasma (1) Upper Gastrointestinal Bleeding (UGIB) (1)
small molecule (6), protein or peptide (3)
The First Affiliated Hospital with Nanjing Medical University (1) New York Medical College (1) University Health Network, Toronto (1) Ascension Health (1) Jiangsu Jingze Biopharmaceutical (1) Massachusetts General Hospital (1) Supergene (1) Youssef Yammine (1) Children's National Research Institute (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.